An Upregulation in the Expression of Vanilloid Transient Potential Channels 2 Enhances Hypotonicity-Induced Cytosolic Ca\(^{2+}\) Rise in Human Induced Pluripotent Stem Cell Model of Hutchinson Gillford Progeria

Chun-Yin Lo\(^1\), Yung-Wui Tjong\(^1\), Jenny Chung-Yee Ho\(^2\), Chung-Wah Siu\(^2\), Sin-Ying Cheung\(^1\), Nelson L. Tang\(^3\), Shan Yu\(^4\), Hung-Fat Tse\(^2\)*, Xiaoqiang Yao\(^1\)*

\(^1\)School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China, \(^2\)Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, \(^3\)Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China, \(^4\)School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

Abstract

Hutchinson-Gillford Progeria Syndrome (HGPS) is a fatal genetic disorder characterized by premature aging in multiple organs including the skin, musculoskeletal and cardiovascular systems. It is believed that an increased mechanosensitivity of HGPS cells is a causative factor for vascular cell death and vascular diseases in HGPS patients. However, the exact mechanism is unknown. Transient receptor potential (TRP) channels are cationic channels that can act as cellular sensors for mechanical stimuli. The aim of this present study was to examine the expression and functional role of TRP channels in human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) from the patients with HGPS. The mRNA and protein expression of TRP channels in HGPS and control (IMR90) iPSC-ECs were examined by semi-quantitative RT-PCRs and immunoblots, respectively. Hypotonicity-induced cytosolic Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) rise in iPSC-ECs was measured by confocal microscopy. RT-PCRs and immunoblots showed higher expression levels of TRPV2 in iPSC-ECs from HGPS patients than those from normal individuals. In functional studies, hypotonicity induced a transient [Ca\(^{2+}\)]\(_i\) rise in iPSC-ECs from normal individuals but a sustained [Ca\(^{2+}\)]\(_i\) elevation in iPSC-ECs from HGPS patients. A nonselective TRPV inhibitor, ruthenium red (RuR, 20 μM), and a specific TRPV2 channel inhibitor, tranilast (100 μM), abolished the sustained phase of hypotonicity-induced [Ca\(^{2+}\)]\(_i\) rise in iPSC-ECs from HGPS patients, and also markedly attenuated the transient phase of the [Ca\(^{2+}\)]\(_i\) rise in these cells. Importantly, a short 10 min hypotonicity treatment caused a substantial increase in caspase 8 activity in iPSC-ECs from HGPS patients but not in cells from normal individuals. Tranilast could also inhibit the hypotonicity-induced increase in caspase 8 activity. Taken together, our data suggest that an up-regulation in TRPV2 expression causes a sustained [Ca\(^{2+}\)]\(_i\) elevation in HGPS-iPSC-ECs under hypotonicity, consequently resulting in apoptotic cell death. This mechanism may contribute to the pathogenesis of vascular diseases in HGPS patients.

Introduction

Hutchinson-Gillford progeria syndrome (HGPS) is a fatal genetic disorder characterized by premature aging in multiple organs including the skin, musculoskeletal and cardiovascular systems [1,2]. HGPS patients suffer from early severe cardiovascular diseases which are characterized by progressive atherosclerosis [3,4], adventitial fibrosis and left ventricular hypertrophy [5]. They typically die from myocardial infarction or ischemic attack at the average age of 13 [6]. HGPS belongs to laminopathies associated with point mutations in nuclear A/C lamin gene (LMNA), which results in the production of a truncated lamin A protein known as progerin. Lack of normal lamin A and accumulation of progerin result in abnormal nuclear envelope shape and chromatin architectures [7,8], and causes disruption of cell division [9,10]. A recent study showed that cytosolic Ca\(^{2+}\) may cause a conformational change in progerin, affecting its posttranslational processing, which may be crucial for disease pathogenesis [11]. However, the mechanisms of premature atherosclerosis and death in HGPS patients remain obscure.

Studies have showed that HGPS cells display an increase in mechanosensitivity [9,10], which may be associated with a decrease in viability and an increase in apoptosis under repetitive mechanical strain [9]. Vascular cells, including vascular smooth muscle cells and endothelial cells, are the primary targets of progerin accumulation [10]. These cells are constantly exposed to fluid shear stress and mechanical strain in the vessel wall [9].
Moreover, it has been suggested that an increase in mechanical sensitivity of vascular cells from HGPS patients may impair cell cycle activation, which contributes to necrotic and apoptotic vascular cell death, leading to severe vascular diseases including atherosclerosis [9]. Although an increase in mechanosensitivity of HGPS vascular cells appears to play a critical role in vascular cell death and cardiovascular diseases, there are still no reports on “mechanosensors” that serve to monitor mechanical stimuli in HGPS vascular cells.

Transient receptor potential (TRP) channels are nonselective cation channels that comprise of six subfamilies: TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), TRPA (ankyrin) and TRPV (vanilloid) [12]. These channels function to perceive and respond to various environmental stimuli, such as thermal, heat, pain, pH, mechanical and osmotic stress [12,13]. TRP channels have been implicated in several cardiovascular diseases including atherosclerosis [14], hypertension [15,16], vascular remodeling, and cardiac hypertrophy [17]. Most TRP channels are Ca\(^{2+}\)-permeable. Mechano-activation of these TRP channels results in Ca\(^{2+}\) influx. Excessive Ca\(^{2+}\) influx or Ca\(^{2+}\) overload are known to contribute to apoptotic and necrotic vascular cell death [14,17–19].

Our recent studies showed that human induced pluripotent stem cell (iPSC) could be derived from normal subjects as well as from patients with HGPS [20–22]. Moreover, iPSC-derived vascular cells from HGPS patients are a good model for studying the correlation between premature senescence phenotypes and vascular ageing [21]. The aim of this present study was to explore the possible role of TRP channels in mechanosensation in iPSC-derived endothelial cells (iPSC-ECs) from HGPS patients.

**Results**

Hypotonicity-induced \([\text{Ca}^{2+}]\), rise in iPSC-ECs from HGPS patients and normal individuals

We used a single wavelength dye Fluo-4 to measure \([\text{Ca}^{2+}]\) change. Figure 1A and 1B show the effect of hypotonicity on \([\text{Ca}^{2+}]\), in the iPSC-ECs derived from normal individuals (IMR90-iPSC-ECs) and HGPS patients (HGPS-iPSC-ECs), respectively. Upon perfusion with hypotonic solution (210 mOsm), \([\text{Ca}^{2+}]\), increased rapidly and peaked within 54±7 sec in IMR90-iPSC-ECs and 67±4 sec in HGPS-iPSC-ECs. Subsequently, elevated \([\text{Ca}^{2+}]\), gradually reverted back to its resting level in IMR90-iPSC-ECs with F1/F0 value of 1.0±0.1 (n = 6). In contrast, \([\text{Ca}^{2+}]\), elevation in HGPS-iPSC-ECs sustained with the F1/F0 value maintained at ~3.0 over 10 min (n = 7) (Figure 1A and B). In the absence of extracellular \(\text{Ca}^{2+}\), hypotonicity failed to induce \([\text{Ca}^{2+}]\), rise in both cell types (Figure 1C), suggesting that the hypotonicity-induced \([\text{Ca}^{2+}]\), rise was mostly due to \(\text{Ca}^{2+}\) influx but not intracellular \(\text{Ca}^{2+}\) store release. Basal \([\text{Ca}^{2+}]\), level was measured

---

**Figure 1. Effect of hypotonicity and ATP on \([\text{Ca}^{2+}]\), in IMR90-iPSC-ECs and HGPS-iPSC-ECs.** (A and B), Representative traces (A) and data summary (B) showing the effect of hypotonicity (210 mOsm) on \([\text{Ca}^{2+}]\), (fluorescence ratio F1/F0) in IMR90-iPSC-ECs and HGPS-iPSC-ECs bathed in isotonic solution. n = 6-7 experiments. (C), Representative traces showing the effect of hypotonic solution (210 mOsm) on \([\text{Ca}^{2+}]\), in cells bathed in \(\text{Ca}^{2+}\)-free isotonic saline. n = 8 experiments. D, Basal \([\text{Ca}^{2+}]\), level in IMR90-iPSC-ECs and HGPS-iPSC-ECs as determined by Fura-2 dye. n = 8. *p<0.01 unpaired t-test compared with the sustained \([\text{Ca}^{2+}]\), level in IMR90-iPSC-EC group in B or compared with basal \([\text{Ca}^{2+}]\), level in D. (E and F), Representative traces showing the effect of ATP (1 \(\mu\)M) on \([\text{Ca}^{2+}]\), in cells bathed in normal physiological saline. Representative from 3 experiments. doi:10.1371/journal.pone.0087273.g001

TRPV2 Mediates Mechanical Ca\(^{2+}\) Rise in HGPS Cells

---
using a dual wavelength ratiometric dye Fura-2. The basal \([\text{Ca}^{2+}]_i\) level was found to be significantly higher in HGPS-iPSC-ECs than in IMR90-iPSC-ECs (Figure 1D). \([\text{Ca}^{2+}]_i\) response to extracellular ATP challenge was also examined. Unlike the responses to hypotonicity, ATP application (1 mM) only induced transient \([\text{Ca}^{2+}]_i\) rise in both cell types. The magnitude of transient \([\text{Ca}^{2+}]_i\), response to ATP was slightly higher in HGPS-iPSC-ECs than that in IMR90-iPSC-ECs (Figure 1E and F). However, because it is well documented that ATP-induced \([\text{Ca}^{2+}]_i\) transients in endothelial cells were mostly due to \(\text{Ca}^{2+}\) release from IP3-sensitive

---

**Figure 2. Expression of TRP channel transcripts in IMR90-iPSC-ECs and HGPS-iPSC-ECs.** Shown were the expressional levels of transcripts for TRPV (A), TRPC (B), TRPM (C) and TRPP (D) in IMR90-iPSC-ECs (I) and HGPS-iPSC-ECs (H). n = 4 independent experiments. *p<0.05 unpaired t-test compared with IMR90-iPSC-ECs.

doi:10.1371/journal.pone.0087273.g002

TRPV2 Mediates Mechanical \(\text{Ca}^{2+}\) Rise in HGPS Cells
traces of TTHH2 in HEK293 cells (Figure 3C). Similar results were obtained in non-transfected HEK293 cells (Figure 3C).

The specificity of anti-TRPV2 antibody was verified. The TRPV2 antibody could recognize expected TRPV2 bands in TRPV2-overexpressing HEK293 cells (Figure 3C), similar to previous reports by others [24]. No bands were observed in non-transfected HEK293 cells (Figure 3C).

The effects of TRPV2 inhibitors on hypotonicity-induced [Ca2+]i rise

TRPV2 has been known to be a mechanosensitive channel [25,26]. To determine whether TRPV2 was involved in hypotonicity-induced [Ca2+]i influx, a nonselective TRPV inhibitor ruthenium red (RuR) and a TRPV2-specific inhibitor tranilast were used. RuR (20 μM) completely abolished the sustained phase of hypotonicity-induced [Ca2+]i rise in HGPS-iPSC-ECs (Figure 4D). The agent also substantially inhibited the transient phase of hypotonicity-induced [Ca2+]i rise by about 34% and 36% in IMR90-iPSC-ECs and HGPS-iPSC-ECs, respectively (Figure 4C). Similarly, tranilast (100 μM) abrogated the sustained phase of hypotonicity-induced [Ca2+]i rise in HGPS-iPSC-ECs (Figure 5D), and also substantially inhibited the transient phase of hypotonicity-induced [Ca2+]i rise by 50% (n = 6, p<0.01) and 56% (n = 6, p<0.01) in IMR90-iPSC-ECs and HGPS-iPSC-ECs, respectively (Figure 5C).

The effects of TRPV2 inhibitors on hypotonic-induced caspase 8 activation

The effect of hypotonicity on cellular apoptosis was determined by measuring caspase 8 activity, which has been reported as a hallmark of apoptotic cell death [27]. Hypotonicity treatment for 10 min significantly increased caspase 8 activity in HGPS-iPSC-ECs but not in IMR90-iPSC-ECs (Figure 6). The hypotonicity-induced caspase 8 activation in the HGPS-iPSC-ECs was abolished by 100 μM tranilast treatment (Figure 6).

Discussion

Major findings of the present study are as follows: 1) iPSC-ECs from HGPS patients expressed much higher levels of TRPV2 mRNA and proteins compared to iPSC-ECs from normal individuals. 2) Hypotonicity induced a transient [Ca2+]i rise in iPSC-ECs from normal individuals, but evoked a sustained [Ca2+]i elevation in iPSC-ECs from HGPS patients. 3) The sustained phase of hypotonicity-induced [Ca2+]i rise was completely abrogated by tranilast or RuR in iPSC-ECs from HGPS patients. Furthermore, the transient phase of hypotonicity-induced [Ca2+]i rise was partially inhibited by RuR or tranilast. 4) Hypotonicity treatment for 10 min caused substantial increase in caspase 8 activity in iPSC-ECs from HGPS patients but not in iPSC-ECs from normal individuals. Tranilast could inhibit the hypotonicity-induced increase in caspase 8 activity. Taken together, our data strongly suggested that TRPV2 was a major mechanosensitive channel that contributed to hypotonicity-induced [Ca2+]i rise in iPSC-ECs. More importantly, this channel was exclusively responsible for sustained [Ca2+]i influx under hypotonicity and contributed to apoptotic cell death in HGPS-iPSC-ECs.

It has been well documented that most TRP channels are Ca2+-permeable and many of them, including TRPC1, TRPC5, TRPV2, TRPV4, TRPM3, TRRM7 and TRPP2, can be activated by hypotonicity-induced cell swelling [28]. Thus, we compared the expression profile of TRP channel mRNAs in iPSC-ECs from HGPS patients with that from normal individuals. iPSC-ECs from both subjects expressed multiple hypotonicity-activated TRP channels, including TRPC1, TRPV2, TRPV4, TRPM7 and TRPP2. However, while expression levels of other
TRP channels remained comparable, TRPV2 displayed a higher expression level in HGPS-iPSC-ECs than that in IMR90-iPSC-ECs. Such observation was confirmed by immunoblots. This prompted us to determine whether TRPV2 accounted for the unique phenomenon of sustained \([\text{Ca}^{2+}]_i\) elevation in HGPS-iPSC-ECs. The results showed that both RuR and tranilast could abolish the sustained phase of hypotonicity-induced \([\text{Ca}^{2+}]_i\) rise, suggesting that TRPV2 was the sole component in mediating sustained \([\text{Ca}^{2+}]_i\) entry in response to hypotonicity in these cells.

Both RuR and tranilast could also substantially reduce the transient phase of hypotonicity-induced \([\text{Ca}^{2+}]_i\) rise by 50–60% in both cell types, indicating that TRPV2 also contributed significantly to the transient phase of \([\text{Ca}^{2+}]_i\) rise. The residual component (≈40%) in the transient phase of \([\text{Ca}^{2+}]_i\) rise after RuR or tranilast treatment might be mediated by other mechanosensitive \([\text{Ca}^{2+}]_i\)-permeable channels, such as TRPC1, TRPV4, TRPM7 and TRPP2. Our data agreed with several previous reports, which showed TRPV2 being a hypotonocity-activated channel.

Figure 4. Effect of ruthenium red (RuR) on hypotonicity-induced \([\text{Ca}^{2+}]_i\) rise. (A-B), Representative traces showing the effect of RuR (20 \(\mu\text{M}\)) on hypotonicity-induced \([\text{Ca}^{2+}]_i\) rise in IMR90-iPSC-ECs (A) and HGPS-iPSC-ECs (B). (C and D), Summarized data showing the effect of RuR on transient phase (C) and sustained phase (D) of hypotonicity-induced \([\text{Ca}^{2+}]_i\) rise. n = 6–7 independent experiments, 5–10 cells per experiment. **/## \textit{p}<0.01 or \textit{p}<0.01 unpaired \textit{t}-test compared with corresponding vehicle control. doi:10.1371/journal.pone.0087273.g004
channel in other cell types, including murine aortic smooth muscle [25] and mouse odontoblasts [26].

Our findings may have significant pathological significance. HGPS cells displayed an increase in mechanosensitivity [9,10]. Such increase in mechanosensitivity has been suggested to be a causative factor for necrotic and apoptotic vascular cell death, contributing to severe vascular diseases such as atherosclerosis [9]. However, the underlying mechanism of how an increase in mechanosensitivity could lead to cell death was not known. This present study provided a mechanistic explanation. From our results, it is conceivable that mechanical strain may stimulate TRPV2, which was excessively expressed in HGPS vascular cells and caused a sustained Ca^{2+} entry, leading to Ca^{2+} overload and subsequent vascular cell death. Indeed, our data clearly showed that TRPV2 mediated the hypotonicity-induced activation of caspase 8, an index for apoptosis, in iPSC-ECs from HGPS patients. These data were in agreement with the generally accepted notion that Ca^{2+} overload could result in cell death [17,18]. Interestingly, TRPV2-mediated Ca^{2+} overloading was previously reported to contribute to muscular dystrophy and/or cardiomyopathy in humans and animal models [29].

In conclusion, we found that an upregulation in TRPV2 expression is responsible for the sustained [Ca^{2+}], elevation under mechanical stress in iPSC-ECs from HGPS patients. This could be an underlying reason for mechanical stress-induced vascular cell death in HGPS patients.

Figure 5. Effect of tranilast on hypotonicity-induced [Ca^{2+}]i rise. (A-B), Representative traces showing the effect of tranilast (100 μM) on hypotonicity-induced [Ca^{2+}]i rise in IMR90-iPSC-ECs (A) and HGPS-iPSC-ECs (B). (C and D), Summarized data showing the effect of tranilast on transient phase (C) and sustained phase (D) of hypotonicity-induced [Ca^{2+}]i rise. n = 6–7 independent experiments, 5–10 cells per experiment. **p<0.01 unpaired t-test compared with vehicle control.

doi:10.1371/journal.pone.0087273.g005
Total RNA isolation and RT-PCR

Cells were incubated with 1 ml of Trizol reagent (Invitrogen, USA), and total RNA was extracted via following the manufacturer’s instructions. In brief, lysates were mixed with chloroform and centrifuged at 12,000 g for 15 min at 4°C. RNA was precipitated with isopropanol, and washed with 75% ethanol, followed by centrifugation at 7,500 g for 5 min at 4°C. The RNA pellet was air-dried, resuspended in RNase-free water. UV absorbance of the RNA samples was measured using a NanoDrop 3300 Fluorospectrometer (Thermo Fisher Scientific Inc, USA). The ratio of the absorbance at 260 and 280 nm was found to be 2.0, indicated its adequate purity. For cDNA synthesis, 1.5 µg of total RNA was mixed with reverse-transcription master mix using a high-capacity cDNA reverse transcription kit (Applied Biosystems, USA). Reverse transcription reactions were performed in a thermal cycler (Bio-Rad Laboratories Inc, USA). Primer sequences are shown in table 1. cDNA samples (0.4 µl) and primers (0.5 µl) were added with 24.1 µl of AmpliTaqGold® DNA Polymerase (Applied Biosystems, USA). 35 cycles (94°C for 1 min, 58°C for 1 min, 72°C for 1 min) were performed with a PCR machine (PTC-200, MJ Research, USA). The amplified PCR products were run on a 1.5% agarose gels containing ethidium bromide.

Immunoblots

Cells were rinsed with ice-cold PBS, harvested in lysis buffer containing protease inhibitor cocktail tablet (Roche Diagnostics GmbH, Germany), and centrifuged at 14,000 x g for 20 minutes at 4°C. Equal amount of proteins were mixed with laemmi buffer, incubated at 70°C for 3 min. Protein samples were separated by using 12% SDS-polyacrylamide mini-gels. The gels were transferred to polyvinylidene-difluoride membrane using Trans-blot SD semi-dry electrophoretic transfer cell (Bio-Rad Laboratories, USA) and blocked with 5% skimmed milk in TBS buffer at room temperature for 2 hr. The membranes were then incubated with the primary antibodies against TRPV2 (VRL-1) (Novus Biologicals, CO, USA) or β-actin (Santa Cruz Biotechnology Inc., USA) overnight at 4°C. Immunoreactivity was detected with the secondary anti-rabbit or anti-mouse antibody conjugated to HRP (Santa Cruz Biotechnology Inc., USA). The blots were developed using a chemiluminescence’s reagent (Bio-Rad Laboratories, USA), with films being exposed and analyzed using Image J (National Institutes of Health, USA).

[Ca$^{2+}$], measurement

The cells were loaded with 5 µM Fluo-4/AM or 10 µM Fura-2/AM in the presence of 0.02% pluronic F-12 for 1 hr, and maintained in normal physiological saline solution (NPSS). [Ca$^{2+}$], measurement was performed in NPSS, isotonic solution, or hypotonic solution. NPSS contained in mM: 140 NaCl, 5 KCl, 1 MgCl$_2$, 1 CaCl$_2$, 10 glucose, 10 HEPES, pH 7.4. Isotonic solution contained in mM: 63 Na-aspartate, 5 KCl, 1 CaCl$_2$, 1 MgCl$_2$, 10 HEPES, 10 glucose, 140 mannitol, pH 7.4 with NaOH, ~300 mOsm. Hypotonic solution contained in mM: 65 Na-aspartate, 5 KCl, 1 CaCl$_2$, 1 MgCl$_2$, 10 HEPES, 10 glucose, pH 7.4 with NaOH, ~210 mOsm. Fluo-4 fluorescence was recorded and analyzed by FV1000 laser scanning confocal imaging system. [Ca$^{2+}$] response was expressed as a ratio of real-time fluorescence (Ft; excitation at 490 nm) relative to the intensity at the beginning of the experiment (F0), namely Ft/F0. The peak magnitude of the transient phase of hypotonicity-induced [Ca$^{2+}$] rise was measured from the onset of hypotonic stimulation to the peak of [Ca$^{2+}$] rise. The magnitude of sustain phase of [Ca$^{2+}$] rise was measured at 400 sec after hypotonicity treatment.

Figure 6. Effect of tranilast on hypotonicity-stimulated caspase-8 activity. Data summary showing the inhibitory effect of tranilast on hypotonicity-induced activation of caspase-8 in HGPS-iPSC-ECs. n = 6 independent experiments for each group. *p < 0.01 unpaired t-test compared with isotonicity, **p < 0.01 unpaired t-test compared with hypotonicity without tranilast.

doi:10.1371/journal.pone.0087273.g006
Table 1. Primer sequences for PCR amplification of targets and endogenous genes.

| Primer    | Accession numbers | Primer sequence 5'-3'                     |
|-----------|-------------------|------------------------------------------|
| TRPC1     | NM_001251845.1    | Forward 5'-CCAAAGCCCCATGCAGTTGGCT-3'     |
|           |                   | Reverse 5'-AGTGTTGGCTTGGTGCTGGAATAC-3'   |
| TRPC3     | NM_001130698.1    | Forward 5'-TGACTTCCGGTGTGCTCAGTAATAG-3'  |
|           |                   | Reverse 5'-CCTCTCTGAAACTCTCTTCGTAAC-3'   |
| TRPC4     | NM_016179.2       | Forward 5'-TCGCAAATATCTCTGAGAATGAGAG-3'  |
|           |                   | Reverse 5'-AAGCCTTCTGCTGGAATACCTTCAC-3'  |
| TRPC5     | NM_012471.2       | Forward 5'-GGTGAAGTGTTGTGCTAGTGCT-3'     |
|           |                   | Reverse 5'-AGACACGATGGGAACAGAGAAC-3'     |
| TRPC6     | NM_004621.5       | Forward 5'-TGACCGGCTTACCTCATTG-3'        |
|           |                   | Reverse 5'-ATGGAAGAAGTGGCTGTTGAC-3'      |
| TRPC7     | NM_020389.2       | Forward 5'-GGATGCAAGAAGTGGCTGTAAGGC-3'   |
|           |                   | Reverse 5'-CGTCATTTTCTCTGACCTTGAAG-3'    |
| TRPV1     | NM_080704.3       | Forward 5'-GGGAATGTGGGGAAGGAGGAC-3'      |
|           |                   | Reverse 5'-GAGACAGCAATCCGAGAAGAC-3'      |
| TRPV2     | NM_016113.4       | Forward 5'-AGCAGTTGCCGATTGATAGCT-3'      |
|           |                   | Reverse 5'-TTTGTTCAAGGGGCTCAAACAG-3'     |
| TRPV3     | NM_145068.2       | Forward 5'-CGGAGGATAGTGGCTCACCTG-3'      |
|           |                   | Reverse 5'-GGTTGCACCTCTTCTGATAG-3'       |
| TRPV4     | NM_021625.4       | Forward 5'-GGGACATTTCCCAGCATC-3'         |
|           |                   | Reverse 5'-GAGACACGATGTGAGAAGGAC-3'      |
| TRPV5     | NM_019841.4       | Forward 5'-GGGACATTTCCCAGCATC-3'         |
|           |                   | Reverse 5'-CAGTTCAATCAGGGACACAGC-3'      |
| TRPM1     | NM_002420.4       | Forward 5'-GGGACACGATGTGAGAAGGAC-3'      |
|           |                   | Reverse 5'-GAGACACGATGTGAGAAGGAC-3'      |
| TRPM2     | NM_003307.3       | Forward 5'-ACAAACTGTCTGATGGTGACC-3'      |
|           |                   | Reverse 5'-CGAGGATGAAAGTGGCTGTTG-3'      |
| TRPM3     | NM_020952.4       | Forward 5'-ACGAAATGGAAGTGGCTGATAG-3'     |
|           |                   | Reverse 5'-ACCCCAAGCTCATGAGAAAC-3'       |
| TRPM4     | NM_017636.3       | Forward 5'-TACAGGGCAACAGGCTACT-3'        |
|           |                   | Reverse 5'-CTTATGCAAGGCTCAGTGATT-3'      |
| TRPM5     | NM_014555.3       | Forward 5'-TCCCTGATCATGCTGGTGTCA-3'      |
|           |                   | Reverse 5'-CAGTTCAACGAGGCTTCACAA-3'      |
| TRPM6     | NM_017662.4       | Forward 5'-GCAAACACAGAAAAGGCAAGGA-3'     |
|           |                   | Reverse 5'-GTACAGGCAACACACTTCTTTCC-3'    |
| TRPM7     | NM_017672.4       | Forward 5'-GCACAAACAGAAAACCAACAGA-3'     |
|           |                   | Reverse 5'-AGCCTCATAATAGTTGCTCAG-3'      |
| TRPM8     | NM_024080.4       | Forward 5'-GATTGGCCAAAGGAGGACCCG-3'      |
|           |                   | Reverse 5'-CCAGGCAACATGGATGCTG-3'        |
| TRPA1     | NM_007332.2       | Forward 5'-GCTACTTCCTAAAGGAGGCAAGGA-3'   |
|           |                   | Reverse 5'-GTGTTGTGTTGCTCAGCAGC-3'       |
| TRPP1     | NM_001009944.2    | Forward 5'-ATGCCACAGCATGACCTG-3'         |
|           |                   | Reverse 5'-CGTGTGTTGCTCAGCAGC-3'         |
| TRPP2     | NM_000297.2       | Forward 5'-GCAAGTCATGACCTCAGCAGC-3'      |
|           |                   | Reverse 5'-AATGCCCCATTTCTGACACTC-3'      |
| β-actin   | NM_001101.3       | Forward 5'-ATGGAAGATGAAGTCCCGCAGC-3'     |
|           |                   | Reverse 5'-CTTCCATCCTCAGTGCT-3'          |

doi:10.1371/journal.pone.0087273.t001
The Ca\(^{2+}\)-bound and -unbound Fura-2 fluorescence signals were measured by dual excitation wavelengths at 340 and 380 nm using InCyt Basic Fluorescence Imaging System (Intracellular Imaging, Cincinnati, OH). Resultant fluorescence signals were collected at 510 nm and was used to calculate [Ca\(^{2+}\)]\(_i\), as described by Grynkiewicz et al. \(^{[32,33]}\). Calibration was done by measuring the fluorescence intensity of Fura-2 dye using commercial Ca\(^{2+}\) concentration standard with precisely known Ca\(^{2+}\) concentration (Molecular Probes, USA). \(R_{\text{min}}\) and \(R_{\text{max}}\) for Fura-2 were obtained by permeabilizing the cells with 10 \(\mu\)M ionomycin in the presence of 5 mM EGTA and 5 mM CaCl\(_2\), respectively \(^{[32,33]}\). All experiments were performed at room temperature (\(\sim\)23\(^\circ\)C).

### Caspase-8 activity assay

The cells were seeded on 96-well plate (Corning, 3792) coated with Matrigel\(^{TM}\) (BD Biosciences, MA) with mTeSR\(^{TM}\) medium (Stem Cell Technologies, BC, Canada). Cells were grown for 48 hrs and then were incubated with hypotonic or isotonic solution in the presence of 5 mM EGTA and 5 mM CaCl\(_2\), respectively. \(^{[32,33]}\) R min and R max for Fura-2 were obtained by permeabilizing the cells with 10 \(\mu\)M ionomycin in the presence of 5 mM EGTA and 5 mM CaCl\(_2\), respectively \(^{[32,33]}\). All experiments were performed at room temperature (\(\sim\)23\(^\circ\)C).

### Data analysis

Statistical analysis

Data were expressed as mean \(\pm\) SE. Statistical significance was determined by the unpaired student t-test and differences were considered significant at *\(P<0.05\).*

### Author Contributions

Conceived and designed the experiments: H-FT XY C-WS N-LT. Performed the experiments: G-YL Y-WT S-YC. Analyzed the data: C-YL Y-WT SY. Contributed reagents/materials/analysis tools: JC-YH. Wrote the paper: Y-WT XY.

### References

1. Pollex RL, Hegle RA. (2004) Hutchinson-Gilford progeria syndrome. Clin Genet 66: 375–391.
2. Merideh MA, Gordon LB, Claus S, Sachdev V, Smith AC, et al. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358: 592–604.
3. Kiezun MW, Gordon L, Kleinman M. (2007) New approaches to progeria. Pediatrics 119: 834–841.
4. Silvéria VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, et al. (2012) Imaging Characteristics of Cerebrovascular Arteriopathy and Stroke in Hutchinson-Gilford Progeria Syndrome. AJNR Am J Neuroradiol 34: 1091–1097.
5. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, et al. (2010) Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 30: 2301–2309.
6. Capell BC, Collins FS, Nabel EG. (2007) Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 101: 13–26.
7. McCord R, Nazario-Toole A, Zhang H, Chines P, Zhan Y, et al. (2013) Correlated alterations in genome organization, histone methylation, and DNA-lamin A/C interactions in Hutchinson-Gilford progeria syndrome. Genome Res 23: 260–269.
8. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423: 293–298.
9. Reddy S, Comai L. (2012) Lamin A, farnesylation and aging. Exp Cell Res 318: 1–7.
10. McClintock D, Gordon LB, Djabali K. (2006) Hutchinson-Gilford progeria syndrome. Nature 423: 293–298.
11. Pollex RL, Hegle RA. (2004) Hutchinson-Gilford progeria syndrome. Clin Genet 66: 375–391.
12. Merideh MA, Gordon LB, Claus S, Sachdev V, Smith AC, et al. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358: 592–604.
13. Kiezun MW, Gordon L, Kleinman M. (2007) New approaches to progeria. Pediatrics 119: 834–841.
14. Silvéria VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, et al. (2012) Imaging Characteristics of Cerebrovascular Arteriopathy and Stroke in Hutchinson-Gilford Progeria Syndrome. AJNR Am J Neuroradiol 34: 1091–1097.